SBIR/STTR Research Award
Cannabinergic Receptor Antagonists for Nicotine Addiction
Award amount
$214,936Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MAKSCIENTIFIC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- J2NHTDAJGK24
- Solicitation number
- PA13-234
- Topic code
- NIDA
Research abstract
DESCRIPTION (provided by applicant): Existing evidence in animals and man indicates that blockade of the CB1 receptor may offer an effective approach for combating nicotine addiction. Early studies in humans have documented these effects. This Phase I application proposes studies to design advanced CB1 pyrrolidinone antagonists toward the development of medications for smoking cessation. Our intention is to: 1) develop CB1 antagonists with limited inverse agonist or neutral antagonist activity and 2) to characterize their ability to attenuate th effects of nicotine in behavioral screening assays in rats that can be conducted within the limits of a Phase I program. We expect to forward the most successful compounds from Phase I into Phase II studies, in whichwe shall pursue a more detailed lead optimization program, characterize compounds for side-effect liability, and evaluate their ability to reduce addiction-related effects of nicotine in established, addiction-related, self- administration studies in
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A CB1 Antagonist for Treatment of Kidney Disease
- Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
- Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases
- NAAA Inhibitors as Anti inflammatory Agents Phase II
- NAAA Inhibitors as Anti-Inflammatory Agents
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
14 SBIR/STTR records share this UEI (2004–2024). Reported award amounts total $5,897,840. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services